TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at c
linically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remode
ling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…